BMS

The Access to Medicine (AtM) Foundation last week published a pediatric analysis of additional results from its 2021 AtM Index, finding just 7% of pharmaceutical companies’ R&D is for children under 12, despite significant gaps in treatment options for children.

The report praised GSK, Johnson & Johnson and Sanofi for being “the most active” in developing pediatric versions of products, and also named examples of drugs that “could each make a big difference” for LMICs: Eli…

Twelve leading pharma companies released fourth-quarter and full-year 2020 financial results in February. (Figures exclude exchange rate and portfolio changes where applicable.)

Leading the round, Gilead’s fourth-quarter revenue soared 26% over last year to $7.4 billion, beating consensus estimates by 4%. Veklury (remdesivir) drove the surge with $1.9 billion in quarterly sales: the antiviral now treats one in two hospitalized Covid-19 patients in the United States, according to the…

Basel-based Lonza announced Monday that it will sell its specialty ingredients division to private equity firms Bain Capital and Cinven for $4.7 billion, allowing the CDMO to “refocus its business” on the healthcare industry, according to its press release.

In other CDMO news, Shanghai-based WuXi AppTec subsidiary WuXi STA announced last week that it will buy Bristol Myers Squibb’s tablet and capsule manufacturing facility in Couvet, Switzerland for an undisclosed price. WuXi AppTec’s…

Mentions:

The state of the hunt:

Novavax’s protein-based vaccine candidate demonstrated 89.3% efficacy in a UK Phase 3 trial.
  J&J/Janssen’s single-dose vaccine was 66% effective against moderate to severe disease in Phase 3.
  Vaccines from J&J, Moderna, Novavax and Pfizer/BioNTech appear less effective against the SARS-CoV-2 variant first identified in South Africa.

 

Vaccines


Approved or authorized vaccines

AstraZeneca’s vaccine…

For the seventh time in a row, GSK topped the Access to Medicine (AtM) Foundation’s ranking of leading pharma companies’ efforts to provide access to their products in low- and middle-income countries, according to the 2021 AtM Index, launched Tuesday. But the new index showed Novartis gaining on GSK compared to 2018—with the difference in scores falling to only 1.2%.

Overall, 17 of the 20 companies in the index improved their assessments, with Pfizer climbing the most to join the…

Covid-19 dominated the 39th J. P. Morgan Healthcare Conference (JPM), held virtually this week instead of at its customary haunt, San Francisco’s Westin St. Francis. Beyond much coronavirus chatter, the event also featured one major M&A announcement (Sanofi touting its $1 billion Kymab buy) and additional vaccine news from companies including GSK (for RSV), Moderna (for flu, HIV and Nipah) and Takeda (for dengue).

BioNTech CEO Uğur Şahin announced the German company’s plans to…

UK-based Exscientia announced last week a $4.2 million drug discovery grant from the Gates Foundation to use the company’s AI-driven platforms to find small molecule candidates for malaria, non-hormonal contraceptives and tuberculosis.

Exscientia has drug discovery collaborations with several companies, including Bayer, Bristol Myers Squibb, GSK and Sanofi.

Six leading pharma companies released third-quarter financial results in November. (Figures exclude exchange rate and portfolio changes where applicable.)

Leading the round, SK Bioscience’s third-quarter sales surged 98% year-over-year to $89.7 million, driven by skyrocketing flu shot sales and robust performances from its shingles and varicella vaccines. The SK Chemicals subsidiary expects revenues from its contract manufacturing business and flu vaccines to decline in the next…

Bristol Myers Squibb (BMS) announced Monday that it will acquire California-based MyoKardia for $13.1 billion in cash. The transaction adds a potential first-in-class hypertrophic cardiomyopathy treatment (mavacamten) and two clinical-stage novel drugs (danicamtiv and MYK-224) to BMS’s cardiovascular portfolio alongside blockbuster blood thinner Eliquis.

Mentions:

Seven leading pharma companies released second-quarter financial results in August. (Figures exclude exchange rate and portfolio changes where applicable.)

Leading the round, South Korea’s LG Chem posted 2.3% growth year-over-year, reaching $6 billion in quarterly sales. LG Life Sciences—which houses vaccines and drugs—saw quarterly sales up 4% from last year to $138 million. Life Sciences signed multiple deals in August, including an agreement worth up to $98.5 million with Britain’s…